Literature DB >> 29191665

Augmenting Total Body Irradiation with a Cranial Boost before Stem Cell Transplantation Protects Against Post-Transplant Central Nervous System Relapse in Acute Lymphoblastic Leukemia.

Robert W Gao1, Kathryn E Dusenbery2, Qing Cao3, Angela R Smith4, Jianling Yuan5.   

Abstract

The purpose of this study was to determine the effect of a pretransplant cranial boost (CB) on post-transplant central nervous system (CNS) relapse and survival in acute lymphoblastic leukemia (ALL) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) using a total body irradiation (TBI)-containing preparation regimen. Two hundred thirteen ALL patients were treated consecutively at our institution with allogeneic HSCT. Conditioning included TBI (1320 cGy in 8 fractions given twice daily) and cyclophosphamide (120 mg/kg) with or without fludarabine (75 mg/m2). Patients were divided into 4 groups based on history of CNS disease and whether a CB was given. Of the 160 patients with no history of CNS disease, none received a CB (CNS-/CB-). Of the 53 patients with prior CNS disease, 41 had not received prior cranial irradiation. Thirty of these 41 received a CB of 900 to 1000 cGy in 5 daily fractions (CNS+/CB+), whereas the other 11 did not receive a CB because of physician preference (CNS+/CB-). The remaining 12 patients with prior CNS involvement had previously received cranial irradiation and thus were not candidates for a CB (CNS + PriorRT). Two-year CNS relapse risk, overall survival (OS), and disease-free survival (DFS) were calculated using Kaplan-Meier analysis. Seven patients experienced post-transplant CNS relapse: 4 in the CNS-/CB- group, 2 in the CNS+/CB- group, and 1 in the CNS + PriorRT group. None of the 30 patients who received a CB relapsed in the CNS. Two-year CNS relapse risk was 0% in the CNS+/CB+ group compared with 21% (95% CI, 0% to 45%) in the CNS+/CB- group (P = .03). Two-year OS and DFS did not differ between the groups. In conclusion, among ALL patients with prior CNS leukemia, there was a trend toward a reduced risk of post-transplant CNS relapse in patients who received a CB. However, the addition of a CB did not appear to have an impact on OS or DFS.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute lymphocytic leukemia; Allogeneic hematopoietic stem cell transplantation; Central nervous system relapse; Cranial boost; Total body irradiation

Mesh:

Substances:

Year:  2017        PMID: 29191665      PMCID: PMC6692175          DOI: 10.1016/j.bbmt.2017.11.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  24 in total

1.  Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia.

Authors:  F E Halberg; J H Kramer; I M Moore; W M Wara; K K Matthay; A R Ablin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.

Authors:  Luciana Annino; Maria Luce Vegna; Andrea Camera; Giorgina Specchia; Giuseppe Visani; Giuseppe Fioritoni; Felicetto Ferrara; Antonio Peta; Stefania Ciolli; Wilma Deplano; Francesco Fabbiano; Simona Sica; Francesco Di Raimondo; Nicola Cascavilla; Antonio Tabilio; Pietro Leoni; Rosangela Invernizzi; Michele Baccarani; Bruno Rotoli; Sergio Amadori; Franco Mandelli
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy.

Authors:  L Löning; M Zimmermann; A Reiter; P Kaatsch; G Henze; H Riehm; M Schrappe
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

4.  Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

Authors:  P S Gaynon; M E Trigg; N A Heerema; M G Sensel; H N Sather; G D Hammond; W A Bleyer
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

5.  Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital.

Authors:  C H Pui; J M Boyett; G K Rivera; M L Hancock; J T Sandlund; R C Ribeiro; J E Rubnitz; F G Behm; S C Raimondi; A Gajjar; B Razzouk; D Campana; L E Kun; M V Relling; W E Evans
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

6.  Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia.

Authors:  Brian M Alexander; Daniel Wechsler; Thomas M Braun; John Levine; Joseph Herman; Gregory Yanik; Raymond Hutchinson; Lori J Pierce
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-22       Impact factor: 7.038

7.  Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.

Authors:  O B Eden; G Harrison; S Richards; J S Lilleyman; C C Bailey; J M Chessells; I M Hann; F G Hill; B E Gibson
Journal:  Leukemia       Date:  2000-12       Impact factor: 11.528

8.  BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).

Authors:  W A Kamps; J P M Bökkerink; F G A J Hakvoort-Cammel; A J P Veerman; R S Weening; E R van Wering; J F van Weerden; J Hermans; R Slater; E van den Berg; W G Kroes; A van der Does-van den Berg
Journal:  Leukemia       Date:  2002-06       Impact factor: 11.528

9.  Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Jorge Cortes; Francis Giles; Sima Jeha; Carlos E Bueso-Ramos; Sherry Pierce; Jianqin Shan; Charles Koller; Miloslav Beran; Michael Keating; Emil J Freireich
Journal:  Cancer       Date:  2004-12-15       Impact factor: 6.860

10.  Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172).

Authors:  Frank G H Hill; Sue Richards; Brenda Gibson; Ian Hann; John Lilleyman; Sally Kinsey; Christopher Mitchell; Christine J Harrison; Osborn B Eden
Journal:  Br J Haematol       Date:  2004-01       Impact factor: 6.998

View more
  8 in total

1.  Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Authors:  Qi Chen; Xiao-Lu Zhu; Xin Zhao; Xiao Liu; Hai-Xia Fu; Yuan-Yuan Zhang; Yu-Hong Chen; Xiao-Dong Mo; Wei Han; Huan Chen; Chen-Hua Yan; Yu Wang; Ying-Jun Chang; Lan-Ping Xu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Ann Hematol       Date:  2021-01-02       Impact factor: 3.673

Review 2.  An Overview of Autophagy in Hematopoietic Stem Cell Transplantation.

Authors:  Soheila Montazersaheb; Ali Ehsani; Ezzatollah Fathi; Raheleh Farahzadi; Ilja Vietor
Journal:  Front Bioeng Biotechnol       Date:  2022-05-23

Review 3.  A narrative review of central nervous system involvement in acute leukemias.

Authors:  Dalma Deak; Nicolae Gorcea-Andronic; Valentina Sas; Patric Teodorescu; Catalin Constantinescu; Sabina Iluta; Sergiu Pasca; Ionut Hotea; Cristina Turcas; Vlad Moisoiu; Alina-Andreea Zimta; Simona Galdean; Jakob Steinheber; Ioana Rus; Sebastian Rauch; Cedric Richlitzki; Raluca Munteanu; Ancuta Jurj; Bobe Petrushev; Cristina Selicean; Mirela Marian; Olga Soritau; Alexandra Andries; Andrei Roman; Delia Dima; Alina Tanase; Olafur Sigurjonsson; Ciprian Tomuleasa
Journal:  Ann Transl Med       Date:  2021-01

4.  Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.

Authors:  Christina Peters; Jean-Hugues Dalle; Franco Locatelli; Ulrike Poetschger; Petr Sedlacek; Jochen Buechner; Peter J Shaw; Raquel Staciuk; Marianne Ifversen; Herbert Pichler; Kim Vettenranta; Peter Svec; Olga Aleinikova; Jerry Stein; Tayfun Güngör; Jacek Toporski; Tony H Truong; Cristina Diaz-de-Heredia; Marc Bierings; Hany Ariffin; Mohammed Essa; Birgit Burkhardt; Kirk Schultz; Roland Meisel; Arjan Lankester; Marc Ansari; Martin Schrappe; Arend von Stackelberg; Adriana Balduzzi; Selim Corbacioglu; Peter Bader
Journal:  J Clin Oncol       Date:  2020-12-17       Impact factor: 44.544

Review 5.  Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions.

Authors:  Bianca A W Hoeben; Jeffrey Y C Wong; Lotte S Fog; Christoph Losert; Andrea R Filippi; Søren M Bentzen; Adriana Balduzzi; Lena Specht
Journal:  Front Pediatr       Date:  2021-12-03       Impact factor: 3.418

6.  Pharmacogenetics of the Central Nervous System-Toxicity and Relapse Affecting the CNS in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Judit C Sági; András Gézsi; Bálint Egyed; Zsuzsanna Jakab; Noémi Benedek; Andishe Attarbaschi; Stefan Köhrer; Jakub Sipek; Lucie Winkowska; Marketa Zaliova; Stavroula Anastasopoulou; Benjamin Ole Wolthers; Susanna Ranta; Csaba Szalai; Gábor T Kovács; Ágnes F Semsei; Dániel J Erdélyi
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

7.  A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.

Authors:  Jianyu Weng; Peilong Lai; Le Qin; Yunxin Lai; Zhiwu Jiang; Chenwei Luo; Xin Huang; Suijing Wu; Dan Shao; Chengxin Deng; Lisi Huang; Zesheng Lu; Maohua Zhou; Lingji Zeng; Dongmei Chen; Yulian Wang; Xiaomei Chen; Suxia Geng; Weinkove Robert; Zhaoyang Tang; Chang He; Peng Li; Xin Du
Journal:  J Hematol Oncol       Date:  2018-02-20       Impact factor: 17.388

8.  Successful treatment of acute B lymphoblastic leukemia relapse in the skin and testicle by anti-CD19 CAR-T with IL-6 knocking down: a case report.

Authors:  Ze-Fa Liu; Li-Yun Chen; Jin Wang; Li-Qing Kang; Hua Tang; Yao Zhou; Hai-Xia Zhou; Ai-Ning Sun; De-Pei Wu; Sheng-Li Xue
Journal:  Biomark Res       Date:  2020-05-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.